Non-Invasive Neuromodulation in MS Induced Spastic Paraparesis
Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.
• Signed informed consent.
• Age ≥ 18 years and less than 71 years.
• Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
• EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
• Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.
• Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study.
• No change in disease modifying therapy for at least 3 months prior to screening.
• Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.